Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has presented new phase I clinical data for its cancer therapy candidate HMBD ...

Theialife, a late-stage clinical company advancing innovative therapeutic solutions for ocular diseases, today announced the appointment of Thomas Ruggia as President and Chief Executive Officer. Mr.

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 was ...

AC Development, a Golden-based master and vertical developer, today initiated the first phase of the large-scale mixed-use redevelopment of the CoorsTek manufacturing facility in downtown Golden. The ...

A Zionsville-based developer is preparing for the next phase of development at a 48-acre residential and commercial project along Michigan Road in Zionsville. Pittman Partners plans to build up to 225 ...

Development in Terrell set for about 3,600 homes tees up construction on first section ...